XyloCor Therapeutics, Inc.   Report issue

For profit Phase 2
Founded: Malvern PA United States (2013)

Organization Overview

First Clinical Trial
2020
NCT04125732
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

XyloCor Therapeutics, Inc.

Active Ingredients

Drugs in Phase 2 Trials (1)

advegfxc1 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Angina Pectoris (Phase 2)

Cardiovascular Diseases (Phase 2)

Coronary Artery Disease (Phase 2)

Coronary Disease (Phase 2)

Heart Diseases (Phase 2)

Ischemia (Phase 2)

Myocardial Ischemia (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 1